|Bid||16.07 x 1000|
|Ask||16.20 x 1000|
|Day's Range||15.62 - 16.46|
|52 Week Range||9.73 - 26.25|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Intercept Pharmaceuticals hoping for approval on medication to compete in large and fast-growing market for NASH treatments Continue reading...
Pomerantz LLP is investigating claims on behalf of investors of Genfit SA (“Genfit” or the “Company”) (GNFT). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether Genfit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, NY / ACCESSWIRE / March 2, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA ("Genfit" or the Company") (NASDAQ:GNFT). ...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA ("Genfit" or the Company") (NASDAQ: GNFT). Investors who purchased Genfit securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gnft.
The news raises uncertainty across about efforts across the biopharmaceutical industry to find a treatment.
While not a mind-blowing move, it is good to see that the Genfit SA (EPA:GNFT) share price has gained 23% in the last...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
French biopharmaceutical company hopes to become first to get approval of treatment for liver disorder that affects up to 30 million Americans Continue reading...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.
For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio...
A look at the shareholders of Genfit SA (EPA:GNFT) can tell us which group is most powerful. Institutions often own...
Insider Monkey has processed numerous 13F filings of hedge funds and successful investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...